TY - JOUR
T1 - Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction
AU - Sugimoto, Ken
AU - Ito, Hiroshi
AU - Iwakura, Katsuomi
AU - Ikushima, Masashi
AU - Kato, Akinobu
AU - Kimura, Ryusuke
AU - Tanaka, Koji
AU - Masuyama, Tohru
AU - Ogihara, Toshio
AU - Kawano, Shigeo
AU - Fujii, Kenshi
PY - 2003/4/1
Y1 - 2003/4/1
N2 - The aim of this retrospective study was to assess whether intravenous nicorandil, a hybrid of NO and a KATP channel opener, in conjunction with percutaneous coronary intervention (PCI) improves the long-term prognosis in patients with acute myocardial infarction (AMI). Intravenous nicorandil has already been shown to improve the in-hospital prognosis of patients with anterior AMI. The study population consisted of 272 patients with a reperfused AMI who were admitted during a similar time interval, before (control; n= 114) and after nicorandil treatment (n=158). In the nicorandil group, a 4 mg bolus injection was given, followed by 6 mg/h infusion for 24 h and then oral nicorandil at 15 mg/day for at least 1 month. In the patients with an anterior AMI, left ventricular (LV) function was better and the frequency of LV remodeling was lower after 3 months in the nicorandil group; however, in those with a non-anterior AMI, there were no differences in functional outcome and the frequency of LV remodeling between the 2 groups. The frequency of cardiac events was significantly lower in the nicorandil group, and the use of nicorandil was derived as a potential factor related to freedom from cardiac events (p<0.01, odds ratio=0.27). Nicorandil treatment was associated with better myocardial perfusion and a better functional and clinical outcome than PCI alone, and this beneficial effect was maintained for a long time, particularly in patients with anterior AMI.
AB - The aim of this retrospective study was to assess whether intravenous nicorandil, a hybrid of NO and a KATP channel opener, in conjunction with percutaneous coronary intervention (PCI) improves the long-term prognosis in patients with acute myocardial infarction (AMI). Intravenous nicorandil has already been shown to improve the in-hospital prognosis of patients with anterior AMI. The study population consisted of 272 patients with a reperfused AMI who were admitted during a similar time interval, before (control; n= 114) and after nicorandil treatment (n=158). In the nicorandil group, a 4 mg bolus injection was given, followed by 6 mg/h infusion for 24 h and then oral nicorandil at 15 mg/day for at least 1 month. In the patients with an anterior AMI, left ventricular (LV) function was better and the frequency of LV remodeling was lower after 3 months in the nicorandil group; however, in those with a non-anterior AMI, there were no differences in functional outcome and the frequency of LV remodeling between the 2 groups. The frequency of cardiac events was significantly lower in the nicorandil group, and the use of nicorandil was derived as a potential factor related to freedom from cardiac events (p<0.01, odds ratio=0.27). Nicorandil treatment was associated with better myocardial perfusion and a better functional and clinical outcome than PCI alone, and this beneficial effect was maintained for a long time, particularly in patients with anterior AMI.
KW - Contrast agent
KW - Echocardiography
KW - Microcirculation
KW - Myocardial infarction
KW - Reperfusion
KW - Ventricular function
UR - http://www.scopus.com/inward/record.url?scp=0037390281&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037390281&partnerID=8YFLogxK
U2 - 10.1253/circj.67.295
DO - 10.1253/circj.67.295
M3 - Article
C2 - 12655158
AN - SCOPUS:0037390281
VL - 67
SP - 295
EP - 300
JO - Circulation Journal
JF - Circulation Journal
SN - 1346-9843
IS - 4
ER -